S&P 500   3,851.85
DOW   31,188.38
QQQ   324.93
S&P 500   3,851.85
DOW   31,188.38
QQQ   324.93
S&P 500   3,851.85
DOW   31,188.38
QQQ   324.93
S&P 500   3,851.85
DOW   31,188.38
QQQ   324.93
Log in
NASDAQ:ENDP

Endo International Stock Forecast, Price & News

$7.03
-0.03 (-0.42 %)
(As of 01/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.99
Now: $7.03
$7.38
50-Day Range
$5.25
MA: $6.39
$7.97
52-Week Range
$2.08
Now: $7.03
$8.29
Volume2.72 million shs
Average Volume5.40 million shs
Market Capitalization$1.62 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.41
Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; TESTOPEL for TRT in conditions associated with a deficiency or absence of endogenous testosterone; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; VOLTAREN gel for the relief of joint pain of osteoarthritis; LIDODERM for the relief of pain; TESTOPEL, an implantable pellet indicated for TRT in conditions; EDEX to treat erectile dysfunction; and LIDODERM a topical patch product containing lidocaine. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays; and products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
Endo International logo

MarketRank

Overall MarketRank

1.40 out of 5 stars

Medical Sector

541st out of 1,928 stocks

Pharmaceutical Preparations Industry

267th out of 774 stocks

Analyst Opinion: 1.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ENDP
CUSIP29264F20
Phone011-353-1268-2000
Employees3,172

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.91 billion
Cash Flow$5.09 per share
Book Value($3.82) per share

Profitability

Net Income$-422,640,000.00

Miscellaneous

Market Cap$1.62 billion
Next Earnings Date2/24/2021 (Estimated)
OptionableOptionable
$7.03
-0.03 (-0.42 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ENDP News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Endo International (NASDAQ:ENDP) Frequently Asked Questions

How has Endo International's stock been impacted by Coronavirus?

Endo International's stock was trading at $3.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ENDP shares have increased by 80.7% and is now trading at $7.03.
View which stocks have been most impacted by COVID-19
.

Is Endo International a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Endo International stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENDP, but not buy additional shares or sell existing shares.
View analyst ratings for Endo International
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Endo International?

Wall Street analysts have given Endo International a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Endo International wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Endo International's CEO?

1,428 employees have rated Endo International CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Endo International's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Endo International's next earnings date?

Endo International is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Endo International
.

How were Endo International's earnings last quarter?

Endo International plc (NASDAQ:ENDP) posted its quarterly earnings results on Thursday, November, 5th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.14 by $0.38. The firm had revenue of $634.86 million for the quarter, compared to analyst estimates of $550.63 million. Endo International had a negative return on equity of 85.80% and a negative net margin of 5.30%. The firm's quarterly revenue was down 13.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.66 earnings per share.
View Endo International's earnings history
.

What guidance has Endo International issued on next quarter's earnings?

Endo International issued an update on its FY20 earnings guidance on Thursday, November, 5th. The company provided EPS guidance of $2.50-2.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.14. The company issued revenue guidance of $2.75-2.80 billion, compared to the consensus revenue estimate of $2.70 billion.

What price target have analysts set for ENDP?

6 equities research analysts have issued twelve-month price objectives for Endo International's shares. Their forecasts range from $3.00 to $12.00. On average, they expect Endo International's share price to reach $6.80 in the next twelve months. This suggests that the stock has a possible downside of 3.3%.
View analysts' price targets for Endo International
or view Wall Street analyst' top-rated stocks.

Who are some of Endo International's key competitors?

What other stocks do shareholders of Endo International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Endo International investors own include Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Mallinckrodt (MNK), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Micron Technology (MU), Cleveland-Cliffs (CLF), Pfizer (PFE), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

Who are Endo International's key executives?

Endo International's management team includes the following people:
  • Mr. Blaise Coleman, Pres, CEO & Director (Age 47, Pay $1.9M)
  • Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 49, Pay $1.82M)
  • Mr. Patrick A. Barry, Exec. VP & Pres of Global Commercial Operations (Age 53, Pay $1.47M)
  • Mr. Mark T. Bradley, Exec. VP & CFO
  • Mr. Robert Polke, Exec. VP & Global Head of Operations
  • Mr. Jack D. Boyle, Sr. VP, Controller & Chief Accounting Officer (Age 45)
  • Ms. Ruth Thorpe, Sr. VP of Information Technology & Chief Information Officer
  • Ms. Laure E. Park, Sr. VP of Investor Relations & Corp. Affairs
  • Ms. Susan Williamson, Sr. VP & Chief Compliance Officer
  • Ms. Tracy Basso, Chief HR Officer

What is Endo International's stock symbol?

Endo International trades on the NASDAQ under the ticker symbol "ENDP."

How do I buy shares of Endo International?

Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Endo International's stock price today?

One share of ENDP stock can currently be purchased for approximately $7.03.

How big of a company is Endo International?

Endo International has a market capitalization of $1.62 billion and generates $2.91 billion in revenue each year. The company earns $-422,640,000.00 in net income (profit) each year or $2.38 on an earnings per share basis. Endo International employs 3,172 workers across the globe.

What is Endo International's official website?

The official website for Endo International is www.endo.com.

How can I contact Endo International?

Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.